Superworth

Protalix BioTherapeutics free cash flow PLX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
$7.7M
Latest quarter, Q2 FY26
−$11M
Fiscal year 2025
−$13.6M
−284% on the year before

Protalix BioTherapeutics' free cash flow was $7.7M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$11M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$13.6M−284%
FY2024$7.4Mn/a
FY2023−$2.5Mn/a
FY2022−$25.6Mn/a
FY2021−$11.7Mn/a
FY2020−$26.8Mn/a
FY2019−$20Mn/a
FY2018−$8.4Mn/a
FY2017−$11Mn/a
FY2016−$32.9Mn/a
FY2015−$24.7Mn/a
FY2014−$30.1Mn/a
FY2013−$32.5Mn/a
FY2012−$1.4Mn/a
FY2011−$29.3Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$11Mn/a$7.7M
Q1 FY26$21.3Mn/a$13M
Q4 FY25$1.6M−54%−$13.6M
Q3 FY25−$4.2M−205%−$11.7M
Q2 FY25−$5.7Mn/a−$3.4M
Q1 FY25−$5.4M−249%−$1.6M
Q4 FY24$3.6M+7%$7.4M
Q3 FY24$4Mn/a$7.2M
Q2 FY24−$3.8M−179%−$4.2M
Q1 FY24$3.6Mn/a$4.4M
Q4 FY23$3.3Mn/a−$2.5M
Q3 FY23−$7.3Mn/a−$8.6M

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

CompanyFree cash flow yield
PLXProtalix BioTherapeutics3.7%
PDEXPro DEX3.4%
NATRNatures Sunshine Products8.5%
ELMDElectromed3.8%
UTMDUtah Medical Products4.8%
INFUInfuSystem8.3%
VMDViemed Healthcare7.8%
EMBCEmbectan/m
KEQUKewaunee Scientific11.5%
ICCCImmucell4.5%
ARVNArvinas−43.7%
Peer median4.8%

Where Protalix BioTherapeutics ranks

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.